EI
SGMO

EAM Investors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

EAM Investors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-250,789
Closed -$256K – 349
2024
Q4 		$256K Buy
+250,789
New +$458K 0.04% 251
2018
Q2 		– Sell
-219,415
Closed -$4.17M – 349
2018
Q1 		$4.17M Buy
219,415
+141,416
+181% +$3.02M 0.69% 20
2017
Q4 		$1.28M Sell
77,999
-135,028
-63% -$2.01M 0.23% 175
2017
Q3 		$3.19M Buy
213,027
+101,541
+91% +$1.12M 0.42% 60
2017
Q2 		$981K Buy
+111,486
New +$715K 0.16% 199
2016
Q1 		– Sell
-94,183
Closed -$860K – 338
2015
Q4 		$860K Buy
+94,183
New +$726K 0.11% 291
2014
Q3 		– Sell
-61,248
Closed -$935K – 355
2014
Q2 		$935K Sell
61,248
-17,690
-22% -$254K 0.18% 297
2014
Q1 		$1.43M Sell
78,938
-20,955
-21% -$404K 0.26% 175
2013
Q4 		$1.39M Buy
+99,893
New +$1.15M 0.25% 180

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM Investors's SGMO Position: Q1 2025 in Review

EAM Investors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2025, closing a stake of 250,789 shares — an estimated $256K sold.

EAM Investors first reported a position in SGMO in Q4 2013 and held it in 9 quarters. The position peaked at $4.17M in Q1 2018. 122 funds tracked by Wall St. Rank hold SGMO as of Q1 2025.

  • EAM Investors reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2025 after selling out during the quarter.
  • EAM Investors sold 250,789 SANGAMO THERAPEUTICS INC shares in Q1 2025, an estimated $256K.
  • EAM Investors first reported a position in SANGAMO THERAPEUTICS INC in Q4 2013 and held it in 9 quarters.
  • EAM Investors's SANGAMO THERAPEUTICS INC position peaked at $4.17M in Q1 2018.
  • 122 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2025.

Based on EAM Investors's 13F filing for Q1 2025, filed 13 May 2025.